NCT05262322View on ClinicalTrials.gov

Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation

CompletedOBSERVATIONAL
Enrollment

234

Participants

Timeline

Start Date

February 15, 2019

Primary Completion Date

July 9, 2021

Study Completion Date

July 9, 2021

Conditions
Atrial Fibrillation
Interventions
DRUG

Edoxaban

This was a non-interventional, observational study. No drug was administered in this study.

DRUG

Apixaban

This was a non-interventional, observational study. No drug was administered in this study.

DRUG

Rivaroxaban

This was a non-interventional, observational study. No drug was administered in this study.

Trial Locations (8)

G51 4TF

Queen Elizabeth University Hospital - NHS Greater Glasgow and Clyde, Glasgow

GL1 3NN

Gloucestershire Royal Hospital - Gloucestershire Hospitals NHS Foundation Trust, Gloucester

LE1 5WW

Leicester Royal Infirmary - University Hospitals of Leicester NHS Trust, Leicester

SW17 0QT

St George's Hospital - St George's University Hospital's NHS Foundation Trust, London

NE1 4LP

Royal Victoria Infirmary - Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle

NP20 2UB

Royal Gwent Hospital - Aneurin Beban University Health Board, Newport

TA1 5DA

Musgrove park Hospital - Taunton and Somerset NHS Foundation Trust, Taunton

BA21 4AT

Yeovil District Hospital - Yeovil District Hospital NHS Foundation Trust, Yeovil

All Listed Sponsors
lead

Daiichi Sankyo UK Ltd, a Daiichi Sankyo Company

INDUSTRY

NCT05262322 - Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation | Biotech Hunter | Biotech Hunter